Holen Sie sich die Stockscreener-App
1.06
3.92%
0.04
Vorhandelsmarkt:
1.05
-0.01
-0.94%
Schlusskurs vom Vortag:
$1.02
Offen:
$1.01
24-Stunden-Volumen:
766.23K
Relative Volume:
0.55
Marktkapitalisierung:
$28.70M
Einnahmen:
$642.00K
Nettoeinkommen (Verlust:
$-69.90M
KGV:
-0.1482
EPS:
-7.152
Netto-Cashflow:
$-57.62M
1W Leistung:
-2.75%
1M Leistung:
-28.86%
6M Leistung:
-59.54%
1J Leistung:
-44.79%
1-Tages-Spanne:
$1.01
$1.08
1-Wochen-Bereich:
$1.01
$1.18
52-Wochen-Spanne:
$1.01
$8.08
Bioxcel Therapeutics Inc Stock (BTAI) Company Profile
Firmenname
Bioxcel Therapeutics Inc
Sektor
Telefon
203-643-8060
Adresse
555 LONG WHARF DRIVE, NEW HAVEN, CT
Compare BTAI vs TAK, ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BTAI
Bioxcel Therapeutics Inc
|
1.06 | 28.70M | 642.00K | -69.90M | -57.62M | -7.152 |
TAK
Takeda Pharmaceutical Co Adr
|
17.85 | 57.12B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
121.11 | 49.56B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.70 | 43.86B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
31.77 | 35.89B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
578.54 | 25.06B | 3.18B | 1.33B | 1.04B | 27.90 |
Bioxcel Therapeutics Inc Stock (BTAI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-17 | Eingeleitet | Rodman & Renshaw | Buy |
| 2024-02-21 | Herabstufung | UBS | Buy → Neutral |
| 2023-08-15 | Herabstufung | Mizuho | Buy → Neutral |
| 2023-07-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-03-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-12-01 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-06 | Bestätigt | BofA Securities | Buy |
| 2021-11-15 | Herabstufung | Goldman | Neutral → Sell |
| 2021-04-09 | Eingeleitet | Berenberg | Buy |
| 2021-02-01 | Eingeleitet | UBS | Buy |
| 2020-10-30 | Eingeleitet | Goldman | Buy |
| 2020-09-02 | Eingeleitet | Jefferies | Buy |
| 2020-08-17 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-04 | Eingeleitet | Guggenheim | Buy |
| 2020-04-01 | Eingeleitet | BofA/Merrill | Buy |
| 2020-02-26 | Bestätigt | H.C. Wainwright | Buy |
| 2020-01-08 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
Alle ansehen
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Promise And Dilution Risks - Yahoo Finance
H.C. Wainwright reiterates BioXcel Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Did BioXcel Therapeutics, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - Finviz
BioXcel Therapeutics, Inc. Share Price TodayLive NASDAQ: BTAI Stock Price Charts, History - Upstox
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions - Sahm
BioXcel Therapeutics, Inc. (BTAI) Stock Price, News, Quote & History - Yahoo! Finance Canada
BioXcel Therapeutics, Inc. (BTAI) stock price, news, quote and history - Yahoo Finance Australia
Jobs Data: Is BioXcel Therapeutics Inc a strong candidate for buy and hold2026 Fundamental Recap & Safe Entry Zone Tips - baoquankhu1.vn
BioXcel Therapeutics announces enrollment of first patients in U.S. Department of War-funded study of BXCL501 (sublingual dexmedetomidine) for treatment of acute stress reactions - marketscreener.com
BioXcel begins DoW-funded trial of BXCL501 for acute stress By Investing.com - Investing.com Canada
BioXcel Therapeutics Announces Enrollment of First Patients - GlobeNewswire
BTAI Forecast, Price Target & Analyst Ratings | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
BTAI Technical Analysis & Stock Price Forecast - Intellectia AI
BioXcel Therapeutics Inc. (BX20.SG) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
BTAI Should I Buy - Intellectia AI
BTAI: HC Wainwright & Co. Lowers Price Target, Maintains Buy Rat - GuruFocus
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright cuts BioXcel Therapeutics price target on dilution - Investing.com
H.C. Wainwright Maintains BioXcel Therapeutics(BTAI.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
FDA accepts BioXcel filing for at-home agitation treatment By Investing.com - Investing.com South Africa
FDA accepts BioXcel filing for at-home use of agitation drug By Investing.com - Investing.com South Africa
FDA accepts BioXcel filing for at-home use of agitation drug - Investing.com Australia
BTAI: FDA Reviews BioXcel's Home Use Application for Igalmi - GuruFocus
FDA Accepts BioXcel sNDA for At-Home IGALMI Use - TipRanks
BioXcel Therapeutics Announces Food and Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - marketscreener.com
FDA accepts BioXcel Therapeutics application for IGALMI in at-home agitation treatment - Investing.com UK
FDA accepts BioXcel filing for at-home agitation treatment - Investing.com
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting - The Manila Times
BioXcel Therapeutics (BTAI) gets FDA review date for IGALMI at-home agitation use - Stock Titan
BTAI.O Forecast — Price Prediction for 2026. Should I Buy BTAI.O? - Intellectia AI
BTAI.O PE Ratio & Valuation, Is BTAI.O Overvalued - Intellectia AI
BTAI.O Technical Analysis & Stock Price Forecast - Intellectia AI
Certain Common Stock of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
Certain Warrants of BioXcel Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 1-APR-2026. - marketscreener.com
BTAI SEC FilingsBioxcel Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI in the At-Home Setting - Bitget
Why are BioXcel Therapeutics shares down Friday? - MSN
Bank of America Securities Remains a Sell on Bioxcel Therapeutics (BTAI) - The Globe and Mail
Qatar Investment Authority (BTAI) reports 156,066 BioXcel shares owned - Stock Titan
Pharvaris (NASDAQ:PHVS) versus BioXcel Therapeutics (NASDAQ:BTAI) Critical Comparison - Defense World
Free cash flow per share of BioXcel Therapeutics, Inc. – FWB:BX20 - TradingView
How The BioXcel Therapeutics (BTAI) Story Is Shifting With BXCL501 Hopes And Dilution Risks - Yahoo Finance
SHAREHOLDER ALERT: Potential Recovery for BioXcel Therapeutics, Inc. (BTAI) Investors Affected by Stock Drop – Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire
Finanzdaten der Bioxcel Therapeutics Inc-Aktie (BTAI)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.06%
1.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):